Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 79 Squamous Cell Carcinoma of Head and Neck 44 Lung Neoplasms 36 Urinary Bladder Neoplasms 22 Oropharyngeal Neoplasms 22 Head and Neck Neoplasms 19 Nasopharyngeal Carcinoma 18 Carcinoma 16 Biliary Tract Neoplasms 15 Small Cell Lung Carcinoma 14 Parkinson Disease 4, Autosomal Dominant Lewy Body 14 Esophageal Squamous Cell Carcinoma 14 Uterine Cervical Neoplasms 13 Neoplasms 13 Neoplasm Metastasis 13 Cholangiocarcinoma 13 Ovarian Neoplasms 12 Colorectal Neoplasms 12 Pancreatic Neoplasms 11 Carcinoma, Squamous Cell 11 Laryngeal Neoplasms 10 Stomach Neoplasms 9 Mouth Neoplasms 9 Gallbladder Neoplasms 8 Endometrial Neoplasms 8 Carcinoma, Transitional Cell 8 Hypopharyngeal Neoplasms 7 Esophageal Neoplasms 7 Triple Negative Breast Neoplasms 6 Mesothelioma, Malignant 6

Interventions

pembrolizumab 2 Carboplatin 2 tislelizumab 1 cemiplimab 1 aflutinib 1 Pemetrexed 1 Docetaxel 1 Cisplatin 1 Axitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Non-small Cell Lung Cancer × Cisplatin × 90 days × Clear all

NCT06452277 2026-05-18

SOHO-02

Bayer

Phase 3 Recruiting

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡